Research progress on application of the combination of radiotherapy and immune-checkpoint blockade in treatment of stage Ⅲ unresectable non-small cell lung cancer
10.3760/cma.j.issn.1004-4221.2019.11.016
- VernacularTitle: 放疗联合免疫检查点抑制剂治疗Ⅲ期不可切除非小细胞肺癌研究进展
- Author:
Rutian LI
1
;
Zhengfei ZHU
2
;
Lifeng WANG
1
;
Jing YAN
1
;
Yingtzu YAN
1
;
Baorui LIU
1
Author Information
1. The Comprehensive Cancer Center of Drum-Tower Hospital, Medical School of Nanjing University, Nanjing, 210008, China
2. Department of Radiation Therapy, Cancer Hospital, Fudan University, Shanghai 200032, China
- Publication Type:Review
- Keywords:
Lung neoplasm/radiotherapy;
Immune-checkpoint blockade;
Research progress
- From:
Chinese Journal of Radiation Oncology
2019;28(11):872-875
- CountryChina
- Language:Chinese
-
Abstract:
Chemoradiation has been the standard treatment of stage Ⅲ unresectable non-small cell lung cancer (NSCLC) for a long period of time. However, the clinical efficacy of chemoradiation has not been significantly improved in recent two decades. In the past 2-3 years, the role of immune-checkpoint inhibitors in metastatic NSCLC has been persistently strengthened. Moreover, the synergistic effect between radiotherapy and immune-checkpoint blockade has been conformed in pre-clinical and clinical studies. Recent clinical trials have demonstrated that the combination of radiotherapy and immune-checkpoint blockade has been proven to be more effective in the treatment of stage Ⅲ unresectable NSCLC. In this article, the latest clinical studies since 2017 regarding the application value of this combined treatment of stage Ⅲ unresectable NSCLC were summarized.
